S&P 500   3,443.12 (+0.47%)
DOW   28,308.79 (+0.40%)
QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
S&P 500   3,443.12 (+0.47%)
DOW   28,308.79 (+0.40%)
QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
S&P 500   3,443.12 (+0.47%)
DOW   28,308.79 (+0.40%)
QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
S&P 500   3,443.12 (+0.47%)
DOW   28,308.79 (+0.40%)
QQQ   284.41 (+0.21%)
AAPL   117.51 (+1.32%)
MSFT   214.65 (+0.20%)
FB   267.56 (+2.36%)
GOOGL   1,551.08 (+1.38%)
AMZN   3,217.01 (+0.31%)
TSLA   421.94 (-2.06%)
NVDA   545.82 (+1.09%)
BABA   309.81 (+1.48%)
CGC   18.88 (-4.69%)
GE   7.34 (+0.69%)
MU   53.53 (+1.71%)
AMD   81.56 (-0.54%)
T   26.76 (-0.45%)
F   7.74 (+1.98%)
ACB   4.56 (-3.18%)
GILD   60.55 (-0.03%)
NFLX   525.42 (-1.00%)
BA   167.24 (+0.08%)
BAC   24.14 (+1.77%)
DIS   124.95 (+0.58%)
Log in
NASDAQ:TNXP

Tonix Pharmaceuticals Stock Forecast, Price & News

$0.70
-0.02 (-2.76 %)
(As of 10/20/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.69
Now: $0.70▼
$0.72
50-Day Range
$0.74
MA: $0.82▼
$0.99
52-Week Range
$0.39
Now: $0.70▼
$4.31
Volume4.94 million shs
Average Volume13.01 million shs
Market Capitalization$91.70 million
P/E RatioN/A
Dividend YieldN/A
Beta1.63
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense. Its lead product candidate is Tonmyar (TNX-102 SL), a proprietary low-dose cyclobenzaprine and sublingual tablet as a bedtime administration, which is in Phase III development for the treatment of posttraumatic stress disorder (PTSD) and Fibromyalgia; and Phase II development for the treatment of agitation in Alzheimer's disease. The company is also developing TNX-601 (tianeptine oxalate) as a daytime administration for the treatment of PTSD and potential indication -neurocognitive dysfunction associated with corticosteroid use that is in pre-investigational new drug (pre-IND) application stage; and TNX-801, a smallpox-preventing vaccine based on a live synthetic version of horsepox virus, which is in pre-IND application stage. Its product pipeline also includes TNX-701, a biodefense development program for protection from radiation injury. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in New York, New York.
Read More
Tonix Pharmaceuticals logo

Beat the Market (BTM) Rank™

Analyst Opinion: 2.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.81 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TNXP
Previous Symbol
CUSIPN/A
CIK1430306
Webwww.tonixpharma.com
Phone212-980-9155
Employees12

Debt

Debt-to-Equity RatioN/A
Current Ratio12.32
Quick Ratio12.32

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.11 per share
Price / Book0.63

Profitability

EPS (Most Recent Fiscal Year)($19.33)
Net Income$-28,620,000.00
Net MarginsN/A
Return on Equity-146.01%
Return on Assets-127.61%

Miscellaneous

Outstanding Shares130,277,000
Market Cap$91.70 million
Next Earnings Date11/13/2020 (Estimated)
OptionableOptionable
$0.70
-0.02 (-2.76 %)
(As of 10/20/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TNXP News and Ratings via Email

Sign-up to receive the latest news and ratings for TNXP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Tonix Pharmaceuticals (NASDAQ:TNXP) Frequently Asked Questions

How has Tonix Pharmaceuticals' stock price been impacted by Coronavirus?

Tonix Pharmaceuticals' stock was trading at $0.8311 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TNXP stock has decreased by 15.3% and is now trading at $0.7039.
View which stocks have been most impacted by COVID-19.

When is Tonix Pharmaceuticals' next earnings date?

Tonix Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, November 13th 2020.
View our earnings forecast for Tonix Pharmaceuticals.

How were Tonix Pharmaceuticals' earnings last quarter?

Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) announced its earnings results on Monday, August, 10th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.21) by $0.02.
View Tonix Pharmaceuticals' earnings history.

When did Tonix Pharmaceuticals' stock split? How did Tonix Pharmaceuticals' stock split work?

Shares of Tonix Pharmaceuticals reverse split on the morning of Wednesday, November 28th 2018. The 1-10 reverse split was announced on Tuesday, November 27th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, November 27th 2018. An investor that had 100 shares of Tonix Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for TNXP?

0 equities research analysts have issued 1-year price targets for Tonix Pharmaceuticals' stock. Their forecasts range from $3.00 to $3.00. On average, they expect Tonix Pharmaceuticals' share price to reach $3.00 in the next twelve months. This suggests a possible upside of 326.2% from the stock's current price.
View analysts' price targets for Tonix Pharmaceuticals.

Are investors shorting Tonix Pharmaceuticals?

Tonix Pharmaceuticals saw a drop in short interest in the month of September. As of September 30th, there was short interest totaling 992,600 shares, a drop of 48.6% from the September 15th total of 1,930,000 shares. Based on an average daily volume of 22,360,000 shares, the days-to-cover ratio is currently 0.0 days.
View Tonix Pharmaceuticals' Short Interest.

Who are some of Tonix Pharmaceuticals' key competitors?

Some companies that are related to Tonix Pharmaceuticals include Trevena (TRVN), Aeglea Bio Therapeutics (AGLE), Syros Pharmaceuticals (SYRS), iBio (IBIO), Kamada (KMDA), Athersys (ATHX), ANI Pharmaceuticals (ANIP), Spero Therapeutics (SPRO), Concert Pharmaceuticals (CNCE), Bicycle Therapeutics (BCYC), MEI Pharma (MEIP), Passage Bio (IMRA), Magenta Therapeutics (MGTA), BioDelivery Sciences International (BDSI) and AC Immune (ACIU).
View all competitors.

What other stocks do shareholders of Tonix Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tonix Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Vaxart (VXRT), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Rite Aid (RAD), Heat Biologics (HTBX), Matinas BioPharma (MTNB), BioNano Genomics (BNGO), VBI Vaccines (VBIV) and ADMA Biologics (ADMA).

Who are Tonix Pharmaceuticals' key executives?

Tonix Pharmaceuticals' management team includes the following people:
  • Dr. Seth Lederman, Co-Founder, Pres, CEO & Chairman (Age 61)
  • Mr. Bradley Saenger, CFO & Treasurer (Age 45)
  • Dr. Gregory M. Sullivan, Chief Medical Officer & Sec. (Age 53)
  • Mrs. Jessica Edgar Morris, Chief Operating Officer
  • Dr. Ronald R. Notvest Ph.D., MBA, Exec. VP of Commercial Planning and Devel.

What is Tonix Pharmaceuticals' stock symbol?

Tonix Pharmaceuticals trades on the NASDAQ under the ticker symbol "TNXP."

How do I buy shares of Tonix Pharmaceuticals?

Shares of TNXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Tonix Pharmaceuticals' stock price today?

One share of TNXP stock can currently be purchased for approximately $0.70.

How big of a company is Tonix Pharmaceuticals?

Tonix Pharmaceuticals has a market capitalization of $91.70 million. The company earns $-28,620,000.00 in net income (profit) each year or ($19.33) on an earnings per share basis. Tonix Pharmaceuticals employs 12 workers across the globe.

What is Tonix Pharmaceuticals' official website?

The official website for Tonix Pharmaceuticals is www.tonixpharma.com.

How can I contact Tonix Pharmaceuticals?

Tonix Pharmaceuticals' mailing address is 509 MADISON AVENUE SUITE 1608, NEW YORK NY, 10022. The company can be reached via phone at 212-980-9155 or via email at [email protected]

This page was last updated on 10/20/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.